Based on the Hong Kong Stock Exchange disclosure on August 28, Betta Pharmaceuticals Co., Ltd. (300558.SZ) has submitted a listing application for the Main Board, with CITIC Securities acting as its sole sponsor.

According to the prospectus, Betta Pharmaceuticals is a major player in China's innovative drug R&D landscape, having successfully evolved from a biotech firm focused on discovery and early development into a commercial-stage biopharmaceutical company with full value-chain capabilities. Alongside this transformation, the company has built an operational platform driven by four synergistic pillars: independent R&D, market expansion, strategic partnerships, and ecosystem development. Since the launch of its first product in 2011, the company has consistently delivered profitability on an annual basis.

Among its marketed drugs, Icotinib (Conmana®/Kaimaina®, an EGFR TKI), Ensartinib (Ensacove®/Beimaina®, an ALK TKI), and Vorolanib (Fumeina®, a VEGFR/PDGFR inhibitor) each represent the first domestically developed drug in their respective classes either approved in China or advancing toward global markets for targeted indications. Icotinib has generated cumulative sales exceeding RMB 18 billion and remains the only first-generation EGFR TKI that continues to compete head-to-head with third-generation alternatives, supported by ongoing life-cycle management and multiple indication expansions.

The company has assembled a comprehensive drug pipeline addressing key lung cancer targets, including EGFR and ALK, while also venturing into promising therapeutic areas such as breast cancer, renal cell carcinoma, hematologic malignancies, and ophthalmology. Betta Pharmaceuticals is dedicated to developing Class 1 innovative drugs recognized by the National Medical Products Administration, maintaining a pipeline of over ten clinical programs at various development stages.

In terms of sales channels, the company distributes the majority of its products through wholesale distributors, who then supply end customers, primarily hospitals and retail pharmacies. Currently, the company works with around 170 distributors covering more than 30 provinces, municipalities, and autonomous regions across China. Revenue generated through wholesale distributors accounted for 70.3%, 70.4%, 73.6%, 73.1%, and 74.7% of total revenue for the years 2023, 2024, 2025, and the six-month periods ended June 30, 2025, and 2026, respectively.

Where the numbers stand

Revenue reached approximately RMB 2.456 billion for fiscal 2023, RMB 2.892 billion for fiscal 2024, RMB 3.609 billion for fiscal 2025, and RMB 1.976 billion for the six months ended June 30, 2026. Net profit for the corresponding periods was approximately RMB 334 million, RMB 387 million, RMB 286 million, and RMB 293 million, respectively. Gross margins for the same periods came in at 82.7%, 80.5%, 78.3%, and 75.1%.

Market context

Lung cancer is among the most common and deadliest malignancies worldwide, with incidence and mortality rates rising in both global and Chinese populations. New global lung cancer cases grew from 2.3 million in 2020 to 2.7 million in 2025, with projections reaching 3.5 million by 2035. In China, new cases rose from 1.0 million in 2020 to 1.1 million in 2025, expected to climb to 1.5 million by 2035.

EGFR-positive lung cancer, defined by the presence of EGFR mutations, is driving expansion in the EGFR TKI market, which is projected to reach USD 23 billion globally by 2035. China's EGFR TKI segment is expected to follow a more balanced and stable growth trajectory, supported by broader applications in combination and sequential therapy regimens, as well as improved patient access. Treatment for EGFR-positive NSCLC in China is becoming increasingly precise and stage-specific. Within this competitive landscape, Betta Pharmaceuticals distinguishes itself with a portfolio that includes both first-generation and third-generation EGFR TKIs—namely, Icotinib and Befotertinib—enabling comprehensive patient management from initial therapy through resistance management.

ALK-positive lung cancer, characterized by ALK mutations, benefits from ongoing advances in second- and third-generation ALK TKIs with improved central nervous system penetration and resistance profiles, alongside expanded molecular testing coverage enabling earlier and more complete detection. China's ALK TKI market previously experienced high growth driven by the rapid adoption of newer generation drugs and enhanced testing rates. Currently, the FDA has approved six ALK TKIs, the EMA five, and the NMPA ten. Ensartinib stands out as the first and only domestically developed ALK TKI to penetrate the global market.

Leadership and ownership

The company's board will be comprised of 12 directors: six executive directors, two non-executive directors, and four independent non-executive directors. Directors serve three-year terms and are eligible for re-election, while independent non-executive directors are limited to a maximum tenure of six consecutive years.

As of August 23, 2026, the company's largest shareholder group comprises Dr. Ding, Kaiming Investment, and Beicheng Investment. Dr. Ding controls approximately 21.50% of total issued share capital through direct ownership (approximately 0.24%) and indirect control via Kaiming Investment (approximately 18.91%) and Beicheng Investment (approximately 2.34%).

Advisory team

Sole sponsor: CITIC Securities (Hong Kong) Limited. Company legal counsel: Cooley HK (Hong Kong and U.S. law), Zhejiang Tiance Law Firm (China law), and Liu Shen & Associates (China IP law). Sole sponsor legal counsel: Davis Polk & Wardwell (Hong Kong and U.S. law) and Commerce & Finance Law Offices (China law). Independent auditor and reporting accountant: BDO Limited. Industry consultant: Frost & Sullivan (Beijing) Co., Ltd. Shanghai Branch. Compliance adviser: Somerley Capital Limited.